

Rapid Drop in CBF Seen at Age 12

BY AMY ROTHMAN SCHONFELD
Contributing Writer

NEW ORLEANS — A sudden decrease in cerebral blood flow at age 12 may reflect underlying neurophysiologic processes heralding the onset of behavioral and cognitive changes that define adolescence.

Whereas previous studies have documented gradual age-associated decreases in cerebral blood flow in normal subjects, by studying a large sample size investigators were able to pinpoint precisely a time of rapid change. The sample included 380 subjects retrospectively identified from a pool of more than 8,000 who had MRI exams with arterial spin labeling perfusion imaging, said Dr. Christopher T. Whitlow, a neuroradiologist at Wake Forest University, Winston-Salem, N.C., who presented his findings at the American Society of Neuroradiology meeting.

Three trends were found after analysis of mean rates of cerebral blood flow (CBF) per year, coinvestigator Dr. Joseph Maldjian, director of the advanced neuroscience imaging research Laboratory at Wake Forest University said in an interview. The first 3 years of life are characterized by a rapid increase in rates of cerebral perfusion.

Dr. Whitlow said the majority of preadolescent subjects (aged 4-11 years) demonstrated whole-brain gray matter perfusion


rates greater than 90 mL/100 g per minute. At that pivotal point, things appear to suddenly and rapidly change, so that by age 12-13 whole-brain gray matter perfusion is less than 90 mL/100 g per minute.

Compared with those of children 4-11 years of age, mean rates of CBF were significantly reduced by 27% among adolescents 12-19 years of age and 31% among young adults 20-30 years of age. There were no statistically significant differences, however,

in rates of CBF between the adolescent and young adult age subgroups.

"The relatively rapid changes in cerebral perfusion that correspond to the onset of adolescence may help to explain the sudden nonlinear nature of marked shifts in emotional, motivational, and cognitive processes associated with this period of development," said Dr. Whitlow.

He plans to explore age-related regional changes in CBF and to correlate CBF changes with hormone status. ■



Mean CBF rates were 27% lower among teens than children 4-11 years of age.

THE ADVANCED NEUROSCIENCE IMAGING RESEARCH LABORATORY/DEPARTMENT OF RADIOLOGY/WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE

The ADC Is Key

DTI from page 1

medial lemniscus resolved, and the pattern of infiltration in the corticospinal tracts and transverse pontine fibers was improved in all patients, he said at the American Society of Neuroradiology meeting.

In two patients with tumoral necrosis at baseline, the corticospinal tracts and posterior transverse pontine fibers appeared disrupted at presentation, and the medial lemnisci were displaced posteriorly. In one patient who presented with mild neurologic symptoms of slurred speech and drooling, initial fiber tract visualization showed infiltrated corticospinal tracts, but the tracts resolved progressively after radiation and remained unchanged with stable disease. The other patient with baseline tumoral necrosis presented with left-sided weakness and ataxia, and the DTI showed infiltration of the right corticospinal tract at presentation. After radiation, the right corticospinal tract showed progressively improved resolution but then was disrupted completely with tumor progression, coinciding with worsening neurologic deficits. In both patients, corticospinal tracts were best resolved when the tumor volume was at a minimum.

Though the series was small, Dr. Vajapeyam says that it demonstrates the value of sequential DTI imaging over time and the ability to correlate DTI findings with neurologic deficits. A larger study may determine if the findings correlate with tumor time to progression or outcome. He envisions DTI providing presurgical guidance in brainstem gliomas.

Dr. Vajapeyam said that he had nothing to disclose. ■

INTRODUCING REQUIP XL

THE ONCE-DAILY ORAL DOPAMINE AGONIST FOR BOTH
EARLY AND ADVANCED PARKINSON'S DISEASE

Once daily for more time in motion

- ✓ One daily dose for smooth delivery¹
- ✓ Simple conversion, simple titration
- ✓ Reduced "off" time by more than 2 hours, relative to baseline, when added to L-dopa^{2**}

Important Safety Information

REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. REQUIP XL should be discontinued if these events occur; it is unknown if dose reduction will eliminate episodes of somnolence. Prescribers should reassess patients for somnolence throughout treatment.

Syncope or symptomatic hypotension may occur, particularly during initial treatment or dose titration. Patients should be cautioned against rising rapidly after sitting or lying down. Elevation of blood pressure and changes in heart rate may also occur.

Because of possible additive effects, caution should be exercised with patients who have sleep disorders or are taking sedating medications, alcohol, CNS depressants, or medications that increase ropinirole plasma levels.

Hallucinations may occur at any time during treatment. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.


Patients should be informed that impulse control symptoms, including compulsive behaviors such as pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped.

Some epidemiologic studies have shown that patients with Parkinson's disease have a higher risk (perhaps 2- to 4-fold higher) of developing melanoma than the general population. Whether the observed increased risk was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, was unclear.

Although REQUIP XL has not been associated with an increased risk of melanoma specifically, its potential role as a risk factor has not been systematically studied. Patients using REQUIP XL should be made aware of these results and should undergo periodic dermatologic screening.

¹A 6-month, randomized, double-blind, placebo-controlled study of 391 patients with Parkinson's disease who were not optimally controlled with L-dopa. As adjunctive therapy to L-dopa, patients were randomized to either REQUIP XL + L-dopa or placebo + L-dopa. The primary end point was mean change from baseline in hours "off" at week 24.
²Relative difference to placebo was 1.7 hours.

For more information about REQUIP XL, visit www.requipxl.com.
Please see Brief Summary of Complete Prescribing Information on the next page.

 GlaxoSmithKline

REQUIP XLTM
(ropinirole
extended-release tablets)